Scientific and Medical Advisory Board

Rene Gonzalez, MD, is Professor of Medicine and of Dermatology and Director of the Melanoma Research Clinics at the University of Colorado Denver (UCD). This comprehensive program includes multi-disciplinary oncology clinics and tumor board. Dr Gonzalez’s clinical interests are malignant melanoma and other cutaneous malignancies; his research interests focus on conventional and experimental treatment of melanoma. Dr. Gonzalez is the principal investigator on numerous national and local therapeutic trials. He is a member of several professional societies including the American Society of Clinical Oncology, the International Society for Biologic Therapy of Cancer, and the Society for Melanoma Research. He has authored or coauthored several book chapters and more than 100 articles and abstracts that have been published in peer-reviewed journals or presented at national or international conferences or symposia.

Mark W. Dewhirst, DVM, PhD, an internationally recognized leader in hyperthermic therapy, and the Gustavo S. Montana Professor of Radiation Oncology and Director of the Radiation Oncology Program of the Duke Comprehensive Cancer Center, has joined our Scientific Advisory Board. Dr. Dewhirst is the Editor-in-Chief of the International Journal of Hyperthermia, and he has directed a clinical program grant to study the use of hyperthermia in the treatment of cancer; themes of the program include establishment of robust methods to measure hyperthermia treatment delivery (i.e. thermal dosimetry), investigation of novel therapeutic opportunities afforded by the use of hyperthermia, and conducting human clinical trials testing the value of hyperthermia when combined with radiation and/or chemotherapy.

Antonio Jimeno, MD, PhD, received his PhD and completed his training in Internal Medicine and Medical Oncology in Madrid, Spain. After complementing his training as a clinical researcher with a Drug Development Fellowship at Johns Hopkins from 2003 to 2006, Dr. Jimeno joined the University of Colorado School of Medicine in 2008, where he is currently an adjunct professor. His research focus is integrating preclinical and clinical drug development approaches with the objective of identifying drugs with the potential of improving treatment options for cancer patients.